Payment overview · 2025
General Payments
$125.64
6 reported records · 5 companies
Healthcare provider profile · identity verified
Stephen J Shields, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLEARWATER, FL · NPI 1427018506
Verified facts
What the public records show
CMS Open Payments records show Stephen J Shields, MD received $125.64 in general payments during 2025 across 6 reported records.
Insmed, Inc. accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insmed, Inc. | Unresolved — no canonical attribution shown | $37.55 | 29.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.59 | 22.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.84 | 19.8% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $18.24 | 14.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.42 | 13.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $108.26 | 5 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $27.59 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 736 | 193 |
| Atorvastatin Calcium | Atorvastatin Calcium | 677 | 196 |
| Lisinopril | Lisinopril | 482 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 459 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 372 | 121 |
| Alprazolam | Alprazolam | 356 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 305 | 87 |
| Losartan Potassium | Losartan Potassium | 279 | 80 |
| Simvastatin | Simvastatin | 278 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 91 |
| Metformin Hcl | Metformin Hcl | 255 | 74 |
| Omeprazole | Omeprazole | 239 | 73 |
| Zolpidem Tartrate | Zolpidem Tartrate | 234 | 44 |
| Trazodone Hcl | Trazodone Hcl | 231 | 56 |
| Gabapentin | Gabapentin | 194 | 65 |
| Furosemide | Furosemide | 189 | 68 |
| Lorazepam | Lorazepam | 176 | 32 |
| Methylprednisolone | Methylprednisolone | 174 | 155 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 49 |
| Tramadol Hcl | Tramadol Hcl | 157 | 53 |
| Allopurinol | Allopurinol | 154 | 47 |
| Eliquis | Apixaban | 150 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 46 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 138 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 41 |
| Celecoxib | Celecoxib | 132 | 38 |
| Potassium Chloride | Potassium Chloride | 129 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 40 |
| Temazepam | Temazepam | 108 | 14 |
| Atenolol | Atenolol | 107 | 29 |
| Warfarin Sodium | Warfarin Sodium | 107 | 26 |
| Sertraline Hcl | Sertraline Hcl | 103 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 94 | 68 |
| Azithromycin | Azithromycin | 92 | 82 |
| Montelukast Sodium | Montelukast Sodium | 88 | 32 |
| Alendronate Sodium | Alendronate Sodium | 87 | 24 |
| Cefuroxime | Cefuroxime Axetil | 87 | 78 |
| Cephalexin | Cephalexin | 86 | 79 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 37 |
| Meloxicam | Meloxicam | 78 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 43 |
| Carvedilol | Carvedilol | 67 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 55 |
| Clonidine Hcl | Clonidine Hcl | 66 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 24 |
| Glipizide | Glipizide | 66 | 20 |
| Memantine Hcl | Memantine Hcl | 64 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 12 |
| Donepezil Hcl | Donepezil Hcl | 58 | 19 |
| Buspirone Hcl | Buspirone Hcl | 56 | 14 |
| Ezetimibe | Ezetimibe | 56 | 15 |
| Synthroid | Levothyroxine Sodium | 56 | 15 |
| Amoxicillin | Amoxicillin | 55 | 48 |
| Januvia | Sitagliptin Phosphate | 55 | suppressed |
| Spironolactone | Spironolactone | 55 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 51 | 27 |
| Finasteride | Finasteride | 51 | 15 |
| Ozempic | Semaglutide | 50 | suppressed |
| Valsartan | Valsartan | 47 | 14 |
| Famotidine | Famotidine | 46 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | suppressed |
| Clonazepam | Clonazepam | 43 | suppressed |
| Ibuprofen | Ibuprofen | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 15 |
| Propranolol Hcl | Propranolol Hcl | 43 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 13 |
| Terazosin Hcl | Terazosin Hcl | 40 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Jantoven | Warfarin Sodium | 38 | suppressed |
| Mirtazapine | Mirtazapine | 37 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Prednisone | Prednisone | 37 | 14 |
| Ramipril | Ramipril | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Glimepiride | Glimepiride | 33 | 11 |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 19 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | 13 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | 12 |
| Metformin Hcl Er | Metformin Hcl | 30 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 23 |
| Baclofen | Baclofen | 29 | 14 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Prolia | Denosumab | 29 | 19 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 17 |
| Topiramate | Topiramate | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | 11 |
| Jardiance | Empagliflozin | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 21 |
| Nadolol | Nadolol | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | 13 |
| Permethrin | Permethrin | 18 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Levofloxacin | Levofloxacin | 17 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Toprol Xl | Metoprolol Succinate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $125.64 · 6 records | Insmed, Inc. | Arikayce, Brinsupri, FARXIGA, General - Pain Management, KISUNLA, Natroba, Spinosad | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error